• 1
    Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 34955.
  • 2
    Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. Journal of Immunology 2000; 164: 616673.
  • 3
    Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66: 19.
  • 4
    Jinushi M, Chiba S, Yoshiyama H et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 2011; 108: 1242530.
  • 5
    Xiang R, Luo YP, Zhou H et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. Journal of Clinical Investigation 2006; 116: 213241.
  • 6
    Wyckoff JB, Wang Y, Lin EY et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007; 67: 264956.
  • 7
    Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology 2002; 196: 25465.
  • 8
    Liu C, Sun CZ, Huang HN, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 2003; 63: 295764.
  • 9
    Chen JM, Dando PM, Rawlings ND et al. Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem 1997; 272: 80908.
  • 10
    Sun XF, Murthy RV, Arbman G, Gao JF, Roodman GD. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 2005; 11: 22939.
  • 11
    von Wasielewski R, Gawenda J, Traub F, Luck HJ, Kreipe H. Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 2007; 102: 16.
  • 12
    Saha V, Patel N, Krishnan S et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. Journal of Clinical Investigation 2009; 119: 196473.
  • 13
    Andrade VA, Jardim CA, Melo FM et al. Nucleoplasmic calcium regulates proliferation of hepatocytes through legumain and reticulon4. Gastroenterology 2009; 136: 62635.
  • 14
    Chen JM, Stevens RA, Barrett AJ. Cloning and characterization of mouse legumain. Mol Biol Cell 1997; 8: 2616.
  • 15
    Barrett AJ, Chen JM, Rawlings ND, Stevens RAE. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett 1998; 441: 3615.
  • 16
    Kalbacher H, Schwarz G, Brandenburg J, Reich M, Burster T, Driessen C. Characterization of legumain. Biological Chemistry 2002; 383: 18136.
  • 17
    Wu WY, Luo YP, Sun CZ et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 2006; 66: 97080.
  • 18
    Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. Journal of Clinical Investigation 2012; 122: 78795.
  • 19
    Trouet A, Passioukov A, Van Derpoorten K et al. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res 2001; 61: 28436.
  • 20
    Guo F, Ishiwata T, Yokoyama M, Asano G. Expression of basic fibroblast growth factor, epidermal growth factor, and their receptors in castrated and testosterone injected rat prostates. Acta Histochemica Et Cytochemica 1997; 30: 1322.
  • 21
    Matsuda K, Maruyama H, Guo F et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 2001; 61: 55629.
  • 22
    Guo F, Das S, Mueller BM, Barbas CF, Lerner RA, Sinha SC. Breaking the one antibody-one target axiom. Proc Natl Acad Sci USA 2006; 103: 1100914.
  • 23
    Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 1996; 93: 148338.
  • 24
    Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 2011; 89: 55763.
  • 25
    Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 71727.
  • 26
    Vonhoff DD, Layard MW, Basa P et al. Risk-factors for doxorubicin-induced congestive heart-failure. Ann Intern Med 1979; 91: 7107.
  • 27
    Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 40921.
  • 28
    Shojaei F, Wu XM, Malik AK et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 2007; 25: 91120.
  • 29
    Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1(+)/CD11b(+) myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 671321.
  • 30
    Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 5365.
  • 31
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 16274.
  • 32
    Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009; 70: 32530.
  • 33
    Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 2636.
  • 34
    Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 78191.
  • 35
    Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 2001; 7: 40805.
  • 36
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 23952.
  • 37
    Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25: 31522.
  • 38
    Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 296471.
  • 39
    Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63: 83605.